- Home
- GNL vs ANIP Comparison
GNL vs ANIP Comparison
Compare GNL & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- ANIP
- Stock Information
- Founded
- GNL 2011
- ANIP 2001
- Country
- GNL United States
- ANIP United States
- Employees
- GNL N/A
- ANIP N/A
- Industry
- GNL Real Estate Investment Trusts
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- GNL Real Estate
- ANIP Health Care
- Exchange
- GNL Nasdaq
- ANIP Nasdaq
- Market Cap
- GNL 1.7B
- ANIP 2.0B
- IPO Year
- GNL N/A
- ANIP N/A
- Fundamental
- Price
- GNL $8.25
- ANIP $84.48
- Analyst Decision
- GNL Buy
- ANIP Strong Buy
- Analyst Count
- GNL 3
- ANIP 7
- Target Price
- GNL $8.67
- ANIP $99.29
- AVG Volume (30 Days)
- GNL 1.3M
- ANIP 418.8K
- Earning Date
- GNL 11-05-2025
- ANIP 11-07-2025
- Dividend Yield
- GNL 9.29%
- ANIP N/A
- EPS Growth
- GNL N/A
- ANIP N/A
- EPS
- GNL N/A
- ANIP 1.67
- Revenue
- GNL $751,333,000.00
- ANIP $826,880,000.00
- Revenue This Year
- GNL N/A
- ANIP $40.23
- Revenue Next Year
- GNL N/A
- ANIP $9.65
- P/E Ratio
- GNL N/A
- ANIP $50.25
- Revenue Growth
- GNL 17.63
- ANIP 48.87
- 52 Week Low
- GNL $6.51
- ANIP $52.50
- 52 Week High
- GNL $8.35
- ANIP $99.50
- Technical
- Relative Strength Index (RSI)
- GNL 63.15
- ANIP 43.79
- Support Level
- GNL $7.76
- ANIP $77.99
- Resistance Level
- GNL $7.97
- ANIP $82.12
- Average True Range (ATR)
- GNL 0.18
- ANIP 4.38
- MACD
- GNL 0.04
- ANIP -0.47
- Stochastic Oscillator
- GNL 95.59
- ANIP 37.03
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.